<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04283916</url>
  </required_header>
  <id_info>
    <org_study_id>7/2020</org_study_id>
    <nct_id>NCT04283916</nct_id>
  </id_info>
  <brief_title>Botulinum Toxin Injection in the Treatment of Open Abdomen</brief_title>
  <official_title>Botulinum Toxin Injection in the Treatment of Open Abdomen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oulu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Oulu</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Botulinum toxin has been widely approved and utilized in the treatment of complex abdominal
      wall hernias. Botulinum toxin has been only randomly studied in the treatment of open
      abdomen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      30 consecutive patients who have open abdomen for any indication, will have 300 IU botulinum
      toxin injected in three spots in either sides of the abdomen within 72 hours of the start of
      open abdomen. The hypothesis is botulinum toxin relaxes abdominal wall musculature to ensure
      better and faster closure of the open abdomen.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 21, 2020</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>30 Days</target_duration>
  <primary_outcome>
    <measure>Abdominal wall closure</measure>
    <time_frame>30 days</time_frame>
    <description>Duration of open abdomen treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intensive care time</measure>
    <time_frame>30 days</time_frame>
    <description>Treatment time in the intensive care unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization</measure>
    <time_frame>30 days</time_frame>
    <description>Time spent in the hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hernia</measure>
    <time_frame>2 years</time_frame>
    <description>Incisional hernia incidence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Re-laparotomies</measure>
    <time_frame>30 days</time_frame>
    <description>Number of abdominal explorations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Enterocutaneus fistula</measure>
    <time_frame>30 days</time_frame>
    <description>Enterocutaneus fistula incidence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abdominal wall closure success rate</measure>
    <time_frame>30 days</time_frame>
    <description>the rate of complite abdominal wall closure</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Open Abdomen</condition>
  <condition>Botulinum Toxin Injection</condition>
  <arm_group>
    <arm_group_label>Botox injection</arm_group_label>
    <description>30 consecutive patients will have 300 IU of botulinum toxin injected to six spots in abdominal wall to gain abdominal wall musculature relaxation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum Toxins</intervention_name>
    <description>Botulinum toxin injection to abdominal wall</description>
    <arm_group_label>Botox injection</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        30 consecutive open abdomen patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Open abdomen

        Exclusion Criteria:

          -  Previous incisional hernia in midline

          -  Patient is not in active treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Elisa M채k채r채inen-Uhlb채ck, M.D.</last_name>
    <phone>+358505794011</phone>
    <email>elisa.makarainen-uhlback@ppshp.fi</email>
  </overall_contact>
  <location>
    <facility>
      <name>Oulu University Hospital</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisa Makarainen-Uhlback</last_name>
      <phone>+35883152282</phone>
    </contact>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 21, 2020</study_first_submitted>
  <study_first_submitted_qc>February 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2020</study_first_posted>
  <last_update_submitted>February 24, 2020</last_update_submitted>
  <last_update_submitted_qc>February 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Oulu</investigator_affiliation>
    <investigator_full_name>Elisa Makarainen-Uhlback</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

